A Phase 1 interventional study of risankizumab and risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-17.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the bioavailability, safety and tolerability of risankizumab following subcutaneous injections in healthy male participants.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 3 Subcutaneous (SC) injections of risankizumab Dose A administered via prepared syringe at Day 1 and followed for 140 days.
Drug: risankizumab
Participants will receive 1 SC injection of risankizumab Dose B administered via syringe pump at Day 1 and followed for 140 days.
Drug: risankizumab
Participants will receive 1 SC injection of risankizumab Dose C administered via syringe pump at Day 1 and followed for 140 days.
Drug: risankizumab
Participants will receive 1 SC injection of risankizumab Dose D administered via prepared syringe at Day 1 and followed for 140 days.
Drug: risankizumab
Subcutaneous Injection via prepared syringe
Also known as: ABBV-066, SKYRIZI
Subcutaneous Injection via syringe pump
Also known as: ABBV-066, SKYRIZI
Maximum Observed Plasma Concentration (Cmax)
Maximum Observed Plasma Concentration
Time frame: Up to 140 Days
Time to maximum observed plasma concentration (Tmax)
Time to maximum observed plasma concentration
Time frame: Up to 140 Days
Area under the plasma concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt)
AUC from time 0 to the time of last measurable concentration
Time frame: Up to 140 Days
AUC from time 0 to infinity (AUCinf)
AUC from time 0 to infinity
Time frame: Up to 140 Days
Terminal phase elimination rate constant (β)
Terminal phase elimination rate constant
Time frame: Up to 140 Days
Terminal phase elimination half-life (t1/2).
Terminal phase elimination half-life
Time frame: Up to 140 Days
Number of Anti-drug antibody (ADA) Titers
Incidence of anti-drug antibodies
Time frame: Up to 140 Days
Number of Participants with Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.
Time frame: Up to 140 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2017 to primary completion in Jun 2018, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab